DK2498756T3 - Tabletformuleringer af neratinibmaleat - Google Patents

Tabletformuleringer af neratinibmaleat Download PDF

Info

Publication number: DK2498756T3
Authority: DK; Denmark
Prior art keywords: neratinibmaleate; tablet formulations; formulations; tablet
Prior art date: 2009-11-09

Application number

DK10779339T

Other languages

English (en)

Other versions

DK2498756T4 (da

Inventor

Muhammad Ashraf

Krishnendu Ghosh

Chimanlall Goolcharran

Mainuddin Mahmud

Arwinder Singh Nagi

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-09

Filing date

2010-11-02

Publication date

2019-11-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2498756(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-02 Application filed by Wyeth Llc filed Critical Wyeth Llc

2019-11-25 Publication of DK2498756T3 publication Critical patent/DK2498756T3/da

2023-03-20 Application granted granted Critical

2023-03-20 Publication of DK2498756T4 publication Critical patent/DK2498756T4/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

DK10779339.0T 2009-11-09 2010-11-02 Tabletformuleringer af neratinibmaleat DK2498756T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25940309P	2009-11-09	2009-11-09
PCT/IB2010/054964 WO2011055303A1 (en)	2009-11-09	2010-11-02	Tablet formulations of neratinib maleate

Publications (2)

Publication Number	Publication Date
DK2498756T3 true DK2498756T3 (da)	2019-11-25
DK2498756T4 DK2498756T4 (da)	2023-03-20

Family

ID=43478191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10779339.0T DK2498756T4 (da)	2009-11-09	2010-11-02	Tabletformuleringer af neratinibmaleat

Country Status (21)

Country	Link
US (2)	US8518446B2 (da)
EP (3)	EP4066821A1 (da)
JP (3)	JP5835883B2 (da)
CN (2)	CN103893140B (da)
AR (2)	AR078952A1 (da)
AU (1)	AU2010316683B2 (da)
CA (1)	CA2780428C (da)
CY (1)	CY1122330T1 (da)
DK (1)	DK2498756T4 (da)
ES (1)	ES2757882T5 (da)
FI (1)	FI2498756T4 (da)
HR (1)	HRP20192026T4 (da)
HU (1)	HUE046606T2 (da)
LT (1)	LT2498756T (da)
NZ (1)	NZ599763A (da)
PL (1)	PL2498756T5 (da)
PT (1)	PT2498756T (da)
RS (1)	RS59599B2 (da)
SI (1)	SI2498756T2 (da)
TW (1)	TWI466690B (da)
WO (1)	WO2011055303A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10351448A1 (de) *	2003-11-04	2005-06-09	Bayer Healthcare Ag	Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN113975393A (zh)	2005-02-03	2022-01-28	综合医院公司	治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt)	2005-11-04	2011-08-16	Wyeth Corp	usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3443961B1 (en)	2008-06-17	2020-10-28	Wyeth LLC	Antineoplastic combinations containing hki-272 and vinorelbine
KR20140069340A (ko)	2008-08-04	2014-06-09	와이어쓰 엘엘씨	4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
KR20160106211A (ko)	2009-04-06	2016-09-09	와이어쓰 엘엘씨	네라티닙을 이용한 유방암의 치료법
DK2498756T4 (da) *	2009-11-09	2023-03-20	Wyeth Llc	Tabletformuleringer af neratinibmaleat
NZ599762A (en)	2009-11-09	2014-07-25	Wyeth Llc	Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP2797597B1 (en)	2011-12-28	2020-02-26	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20142454A1 (es)	2011-12-28	2015-02-07	Global Blood Therapeutics Inc	Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CA2903220C (en)	2013-03-15	2023-01-24	Qing Xu	Aldehyde compounds and uses thereof for the modulation of hemoglobin
CN111454200A (zh)	2013-03-15	2020-07-28	全球血液疗法股份有限公司	化合物及其用于调节血红蛋白的用途
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en)	2013-03-15	2015-10-29	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9818967B2 (en) *	2013-06-28	2017-11-14	Universal Display Corporation	Barrier covered microlens films
CN104337782A (zh) *	2013-08-02	2015-02-11	山东新时代药业有限公司	一种甲磺酸伊马替尼片剂
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
WO2015112850A2 (en) *	2014-01-23	2015-07-30	Wenle Xia	Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
SG10201911668VA (en)	2014-02-07	2020-01-30	Global Blood Therapeutics Inc	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10244991B2 (en)	2014-02-17	2019-04-02	Children's National Medical Center	Method and system for providing recommendation for optimal execution of surgical procedures
ES2857523T3 (es) *	2014-07-25	2021-09-29	Novartis Ag	Formulación en comprimido de 2-fluoro-N-metil-4-[7-(quinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
KR102305932B1 (ko)	2015-06-29	2021-09-28	플로로놀 인코퍼레이티드	갈조류의 고체 약제학적 조성물
SG10201912511WA (en)	2015-12-04	2020-02-27	Global Blood Therapeutics Inc	Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106831710A (zh) *	2015-12-07	2017-06-13	常州爱诺新睿医药技术有限公司	一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN106913529B (zh) *	2015-12-24	2020-12-04	江苏恒瑞医药股份有限公司	一种来那替尼或其可药用盐药物组合物的制备方法
CA2937365C (en) *	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI825524B (zh)	2016-05-12	2023-12-11	美商全球血液治療公司	用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
SG11201901873PA (en) *	2016-09-07	2019-03-28	Celgene Corp	Tablet compositions
TW202332423A (zh)	2016-10-12	2023-08-16	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018201131A1 (en) *	2017-04-28	2018-11-01	Asana Biosciences, Llc	Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
WO2019080830A1 (zh) *	2017-10-24	2019-05-02	江苏恒瑞医药股份有限公司	一种含有喹啉衍生物的药物组合物
US11014884B2 (en)	2018-10-01	2021-05-25	Global Blood Therapeutics, Inc.	Modulators of hemoglobin
IL295007A (en)	2020-01-31	2022-09-01	Nanocopoeia Llc	Amorphous nilotinib microparticles and uses thereof
US20220378788A1 (en) *	2020-04-30	2022-12-01	Nanocopoeia, Llc	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
CA3181361A1 (en) *	2020-04-30	2021-11-04	Nanocopoeia, Llc	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
AU2021291437B2 (en) *	2020-06-19	2024-07-04	Acerta Pharma B.V.	Acalabrutinib maleate dosage forms
WO2023172958A1 (en) *	2022-03-08	2023-09-14	Onkosxcel Therapeutics, Llc	Stable formulations of talabostat
WO2024187321A1 (zh) *	2023-03-10	2024-09-19	甫康（上海）健康科技有限责任公司	含有egfr抑制剂的药物组合物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW442301B (en) *	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6288082B1 (en)	1998-09-29	2001-09-11	American Cyanamid Company	Substituted 3-cyanoquinolines
US6384051B1 (en)	2000-03-13	2002-05-07	American Cyanamid Company	Method of treating or inhibiting colonic polyps
US7399865B2 (en) †	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
AR046544A1 (es) *	2003-10-15	2005-12-14	Wyeth Corp	Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados
US20050142192A1 (en) *	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
AU2005295859A1 (en) *	2004-10-13	2006-04-27	Wyeth	Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2006085168A2 (en) *	2005-01-07	2006-08-17	Ranbaxy Laboratories Limited	Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
ATE460937T1 (de) *	2005-04-28	2010-04-15	Wyeth Corp	Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
EP2340837B1 (en) *	2005-11-11	2017-03-15	Boehringer Ingelheim International GmbH	Combination treatment of cancer comprising egfr/her2 inhibitors
JP2007169273A (ja) *	2005-11-28	2007-07-05	Takeda Chem Ind Ltd	杵付着を改善した医薬製剤
JP2007211005A (ja) *	2006-01-16	2007-08-23	Ono Pharmaceut Co Ltd	固形製剤用組成物および固形製剤
TW200806282A (en) *	2006-05-05	2008-02-01	Wyeth Corp	Solid dosage formulations
AU2008206476A1 (en) *	2007-01-12	2008-07-24	Wyeth	Tablet-in-tablet compositions
TW200836774A (en) *	2007-02-01	2008-09-16	Takeda Pharmaceutical	Solid preparation
JP2009089982A (ja) *	2007-10-11	2009-04-30	Ohara Yakuhin Kogyo Kk	打錠用造粒物の造粒方法
US20090203709A1 (en) *	2008-02-07	2009-08-13	Abbott Laboratories	Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
MX2012000048A (es) *	2009-07-02	2012-01-27	Wyeth Llc	Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos.
DK2498756T4 (da) *	2009-11-09	2023-03-20	Wyeth Llc	Tabletformuleringer af neratinibmaleat

2010
- 2010-11-02 DK DK10779339.0T patent/DK2498756T4/da active
- 2010-11-02 RS RS20191417A patent/RS59599B2/sr unknown
- 2010-11-02 CN CN201410082103.7A patent/CN103893140B/zh active Active
- 2010-11-02 EP EP22169771.7A patent/EP4066821A1/en active Pending
- 2010-11-02 NZ NZ599763A patent/NZ599763A/en unknown
- 2010-11-02 AU AU2010316683A patent/AU2010316683B2/en active Active
- 2010-11-02 CN CN201080060546.6A patent/CN102724970B/zh active Active
- 2010-11-02 FI FIEP10779339.0T patent/FI2498756T4/fi active
- 2010-11-02 PL PL10779339.0T patent/PL2498756T5/pl unknown
- 2010-11-02 WO PCT/IB2010/054964 patent/WO2011055303A1/en active Application Filing
- 2010-11-02 HU HUE10779339A patent/HUE046606T2/hu unknown
- 2010-11-02 EP EP19154710.8A patent/EP3566697B1/en active Active
- 2010-11-02 SI SI201031952T patent/SI2498756T2/sl unknown
- 2010-11-02 PT PT107793390T patent/PT2498756T/pt unknown
- 2010-11-02 LT LT10779339T patent/LT2498756T/lt unknown
- 2010-11-02 ES ES10779339T patent/ES2757882T5/es active Active
- 2010-11-02 CA CA2780428A patent/CA2780428C/en active Active
- 2010-11-02 HR HRP20192026TT patent/HRP20192026T4/hr unknown
- 2010-11-02 EP EP10779339.0A patent/EP2498756B2/en active Active
- 2010-11-05 US US12/940,808 patent/US8518446B2/en active Active
- 2010-11-08 TW TW99138396A patent/TWI466690B/zh active
- 2010-11-08 JP JP2010249385A patent/JP5835883B2/ja active Active
- 2010-11-09 AR ARP100104156A patent/AR078952A1/es not_active Application Discontinuation
2013
- 2013-08-21 US US13/972,764 patent/US8790708B2/en active Active
2015
- 2015-02-06 JP JP2015021870A patent/JP2015091882A/ja not_active Withdrawn
2017
- 2017-02-06 JP JP2017019429A patent/JP2017075192A/ja not_active Withdrawn
2018
- 2018-11-14 AR ARP180103329A patent/AR114143A2/es not_active Application Discontinuation
2019
- 2019-11-14 CY CY20191101200T patent/CY1122330T1/el unknown

Also Published As

Publication number	Publication date
PT2498756T (pt)	2019-11-26
ES2757882T3 (es)	2020-04-30
AU2010316683B2 (en)	2015-10-08
FI2498756T4 (fi)	2023-03-22
AR114143A2 (es)	2020-07-29
CN103893140A (zh)	2014-07-02
NZ599763A (en)	2014-06-27
HRP20192026T4 (hr)	2023-03-31
CY1122330T1 (el)	2021-01-27
PL2498756T5 (pl)	2023-04-17
WO2011055303A1 (en)	2011-05-12
JP2015091882A (ja)	2015-05-14
SI2498756T2 (sl)	2023-04-28
CA2780428A1 (en)	2011-05-12
CN102724970A (zh)	2012-10-10
CN103893140B (zh)	2016-06-01
RS59599B1 (sr)	2020-01-31
SI2498756T1 (sl)	2020-01-31
DK2498756T4 (da)	2023-03-20
US20140004184A1 (en)	2014-01-02
LT2498756T (lt)	2019-12-10
EP2498756B1 (en)	2019-09-04
US8518446B2 (en)	2013-08-27
PL2498756T3 (pl)	2020-03-31
CN102724970B (zh)	2014-06-25
AR078952A1 (es)	2011-12-14
EP3566697B1 (en)	2024-09-11
EP4066821A1 (en)	2022-10-05
ES2757882T5 (es)	2023-05-10
JP5835883B2 (ja)	2015-12-24
EP3566697A1 (en)	2019-11-13
HRP20192026T1 (hr)	2020-02-07
RS59599B2 (sr)	2023-03-31
EP2498756B2 (en)	2023-02-15
TW201138774A (en)	2011-11-16
JP2017075192A (ja)	2017-04-20
JP2011098964A (ja)	2011-05-19
TWI466690B (zh)	2015-01-01
US8790708B2 (en)	2014-07-29
HUE046606T2 (hu)	2020-03-30
EP2498756A1 (en)	2012-09-19
AU2010316683A1 (en)	2012-05-24
CA2780428C (en)	2018-02-13
US20110111018A1 (en)	2011-05-12

Publication	Publication Date	Title
DK2498756T3 (da)	2019-11-25	Tabletformuleringer af neratinibmaleat
CY2020008I2 (el)	2020-11-25	Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
DK2528602T4 (da)	2020-04-27	Formuleringer af bendamustin
SMT201600350B (it)	2016-11-10	Composizioni farmaceutiche
DK3061445T3 (da)	2023-09-11	Højkoncentrerede farmaceutiske formuleringer
BR112012011733A2 (pt)	2019-09-24	formulações de comprimido de liberação imediata
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
DK3721904T3 (da)	2021-11-15	Formuleringer af t1h-antistof
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
BRPI1012539A2 (pt)	2016-03-29	composições farmacêuticas
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
GT201200303A (es)	2014-04-29	Formulaciones farmacéuticas
DK2459129T3 (da)	2019-10-07	Forbedringer af karstøtteanordninger
IT1394400B1 (it)	2012-06-15	Composizioni farmaceutiche
DK2408446T3 (da)	2019-12-09	Anvendelse af farmaceutiske sammensætninger, der indeholder mesembrenon
BRPI1009465A2 (pt)	2015-08-18	Formulação
DK2358714T3 (da)	2012-08-20	Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI0922653A2 (pt)	2016-01-05	preparação farmacêutica
DK2453858T3 (da)	2014-11-03	Fremgangsmåde
CO6801722A2 (es)	2013-11-29	Composiciones farmacéuticas
DK2501381T3 (da)	2017-11-06	Behandling af atrieflimmer
BR112012001340A2 (pt)	2016-03-15	composições farmacêuticas
BR112012003149A2 (pt)	2016-03-01	composição farmacêutica
FR2952847B3 (fr)	2011-12-09	>
BRPI1006076A2 (pt)	2016-04-19	composicoes farmaceuticas